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1. Introduction
Gait impairment, worse equilibrium scores and falls are associated with leukoaraiosis, as
widely recognised [1-6]. In Binswanger’s disease with a severe leukoaraiosis gait disorders are
clearly evident while patients with mild periventricular changes may present subclinical forms
of gait disorders, as proposed by some authors (see data in [7]).
Gait disorders in the elderly are particularly relevant, since they can influence the loss of
functional independence and death [8]. As anticipated, cerebral small vessel disease (both
white matter lesions and lacunar infarcts) correlates with gait parameters: stride length and a
lower gait velocity [8]. Most importantly, subcortical vascular lesions seem to increase the
possibility of falls, even if clear evidences are still lacking [9-11].
Walking difficulties in Alzheimer’s disease are well described [12]: patients show slow and
irregular steps, difficulties in turning and avoiding obstacles [13, 14]. These disturbances have
been described also in patients free from extrapyramidal, ataxic, paretic signs, and clinically
relevant musculoskeletal impairments [12, 14]. Moreover, Alzheimer’s disease patients have
a worse balance [12, 14, 15] and a higher risk of falls compared with matched controls [16, 17].
The prevalence of gait abnormalities varies widely across the studies (from 8.7% [18] to over
90% [19]); this can be explained because of different inclusion criteria and/or assessment
procedures.
These observations have been confirmed by studies demonstrating that patients with Alz‐
heimer’s disease walk more slowly compared to healthy controls [12] and these gait problems
have been interpreted as manifestations of the extrapyramidal deficits (well-known to affect
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12–28% of Alzheimer patients), or as side effects of drug treatment (e.g. neuroleptic agents)
[20]. Since a overt walking problems and trunk movement alterations can be seen also in
absence of extrapyramidal signs, it has been proposed that some Alzheimer’s disease patients
may present “frontal gait disorder”, a syndrome coterminous with gait apraxia [21, 15]. The
lack of a standardised instrument to assess gait has been implicated as a possible cause for the
low frequency of reports on the topic.
Since the walking assessment cannot discriminate between walking disorders caused by gait
apraxia and other neurological causes of walking difficulty, there has been the necessity to
exclude alternative causes of walking abnormalities in Alzheimer’s disease (overt extrapyra‐
midal impairments or other concurrent neurological diseases); in order to assess gait capacity,
a new test has been proposed and a large proportion of the sample (40%) scored below cut off,
even if the percentage of severely impaired was smaller. Although the possibility of right–left
confusion, working memory deficits, and problems with verbal comprehension was mini‐
mised by demonstrating the items, the complexity of some of them might have contributed to
inflating the proportion of patients performing poorly. Even though, the presence of associated
vascular pathology in a few patients also cannot account for the outcome. Neuroradiological
signs of white matter changes were reported in three of the 24 patients (22.5%) in the Della
Sala et al.’s study [12], who scored below cut off in the assessment of walking skills.
Therefore, in a well-defined population suffering from subcortical vascular dementia and
Alzheimer’s disease (standing from a neurological, clinical, and radiological criteria), we tried
to explore gait, balance and equilibrium alterations, and a behavioral complex symptom, such
as apathy, even considering precipitant factors, such as concomitant pathologies and conse‐
quent therapies. We now present an extension of the work, with a speculation on what we
observed for a two-year follow-up.
2. Subjects and methods
2.1. Patients
From June 1st 2010 to June 1st 2013, 155 patients diagnosed with Alzheimer’s disease (AD),
according to NINDCS-ADRDA criteria [22], and 673 patients with subcortical vascular
dementia (according the NINDS-AIREN criteria for probable VaD [23]) (age 65–94 years) have
been examined in Cognitive Disorder Unit Evaluation of the University of Trieste and enrolled
in the present study.
The inclusion criteria were a Mini-Mental State Examination (MMSE) scores of at least 14 and
satisfying the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV) criteria for dementia. As far as neuroimaging is concerned, subcortical VaD (sVAD)
was diagnosed when the CT/MRI scan showed moderate to severe ischemic white matter
changes [24] and at least one lacunar infarct. In order to be enrolled into the study, Alzheimer’s
subjects had to show on brain MRI the classical pattern of atrophy of AD (hippocampal
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atrophy) and display hypoperfusion in temporoparietal and precuneus regions (AD) on
HMPAO-SPECT. The neurologist (RM) assessed independently, after the radiologist’s
opinion, brain CT and/or MRI images and all the diagnoses have been confirmed after a long
term clinical follow-up (12 and 36 months).
Exclusion criteria were: normal pressure hydrocephalus, diagnoses of major stroke or brain
haemorrhage, previous brain tumours, white matter lesions due to specific aetiologies (e.g.
multiple sclerosis, vasculitis, brain irradiation, and genetic forms of vascular dementia such
as CADASIL or CARASIL). Finally, also major psychiatric illness (e.g.. schizophrenia, bipolar
disorders, psychosis, compulsive-obsessive disorders, etc) or central nervous system disorders
and alcoholism were excluded. Also absence of an informed caregiver, unavailability of
neuroradiological examination, and/or the use of psychotropic drugs within two months prior
to the clinical assessment implied patient’s exclusion from the study. According to these
exclusion criteria, 27 AD patients and 70 sVAD patients were excluded. We did not consider
a discriminant/exclusion criteria depression, referring to different studies (such as [25]),
according to the potential correlation to vascular dementia predisposing factor.
2.2. Study design
This was a prospective cohort study, designed to investigate behavioural alterations, and in
particular apathy of a AD and of a sVAD population. Study subjects underwent the following
evaluations. The standardized baseline assessment implied a detailed history, physical
examination (pulse rate and rhythm, blood pressure, heart size and sounds, peripheral pulses,
retinal vessel and carotid artery evaluation), EKG, chest X-ray, laboratory tests and psychiatric
evaluation. All patients were followed with neurological examinations scheduled every four
months, while the complete neuropsychological examination was conducted at baseline and
at 36 months. We conducted the study in accordance with the Declaration of Helsinki and with
the Ethics Guidelines of the Institute.
2.3. Outcome measures
All patients were studied, with complete neurological and neuropsychological examinations.
Main outcomes of the study were: global performance, which was assessed using the Mini
Mental State Examination [26], Frontal Assessment Battery (FAB) [27]; global behavioral
symptoms, assessed by the Neuro Psychiatric Inventory, NPI [28]; the caregiver stress,
assessed by the Relative Stress Scale, RSS [29]. In addition to these main outcome measures,
the Clinical Insight Rating Scale (CIR) [30] (which provides a measure of its four comprising
items – awareness, cognitive deficit, disease progression and functional deficit) was per‐
formed. The Barthel index (BI) [31] and the Instrumental activity of Daily living (IADL) [32]
have been used to assess functional activities and complex activities of daily living, respec‐
tively. Mobility problems were evaluated by the Tinetti scale for equilibrium/balance and gait
[33]: in particular, a semiquantitative assessment was used, consisting of the modified Tinetti
test with 17 items, 9 for body balance (0-16), 8 for gait (0-12). Patients were registered for their
medical intake.




Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS,
version 16.0). Wilcoxon Signed Ranks test was used to analyze the Within-group changes, from
baseline to 24 months, of the overall scores for each efficacy variable.
Behavioral outcome measures, cognition, Tinetti scale, global, balance and equilibrium, and
BI correlations were analyzed applying the Spearman's rank correlation analyses.
4. Results
The study subjects were 128 AD patients and 603 sVAD patients. All the patients could be fully
studied (mean age 72.3 ± 7.3 years, range= 62-94 years). 1 AD patient and 5 sVAD patients died
during the two-year follow-up. As anticipated, the diagnosis based on clinical history,
neuropsychological assessment and neuroimaging was reinforced by subsequent follow-up
in all cases.
All the selected patients underwent neuroimaging: 128 AD patients did MRI studies; 603 sVAD
patients did CT scans; moreover, 201 of the latter completed the diagnostic pathway with MRI
images, in case of not adequate imaging acquisition or not convincing data. Therefore, the
patients who did CT/MRI were homogeneously recruited and no demographical/social/
cultural/clinical difference distinguished from each other.
A neurologist (RM) revised all the imaging, employing the Blennow et al. [34] scale for CT
scans and the Scheltens et al. [35] scale for MRI imaging in sVAD patients and Wahlund et al.
[36], Kantarci et al. [37] and den Heijer et al. [38] criteria for AD MRI imaging. There was 95.8%
inter-rater agreement for the independent assessment of the scans (kappa=0.8).
Patients were allowed to continue any previous therapy (e.g. antihypertensive, antidyslipi‐
demic, antidiabetic drugs). During the follow-up, the patients were prescribed neuroleptics
and/or benzodiazepines.
A synopsis of the cognitive performances obtained by the two groups has been reported in
Table 1-2-3-4.
Baseline sVAD AD P value(between groups)
MMSE 25.8 (2.4) 19.9 (1.9) <0.01
Arithmetic calculations (WAIS) § 6.3 (1.6) 8.6 (1.2) <0.05
Digit span forward (WAIS) 5.8 (1.5) 5.1 (0.6) <0.05
Digit span backward (WAIS) 4.4 (2.5) 2.6 (0.8) <0.05
FAB total score 9.2 (2.1) 11.8 (1.2) <0.05
Table 1. Cognitive synoptical results obtained by the two groups studied. Values are mean (SD); ns = not significant. §
number of mistakes.




(24 months vs baseline)
AD
within group
(24 months vs baseline)
P value
(between groups)
MMSE 20.2 (2.2)(-5.2 (.0.3); p<0.01)
15.1 (1.7)
(-4.85 (0.2); p<0.01) <0.01
Arithmetic calculations (WAIS) § 5.4 (1.1)(-0.9 (0.5); ns)
3.4 (1.7)
(-5.2 (0.5); p<0.01) <0.05
Digit span forward (WAIS) 4.1 (1.4)(-1.7 (0.1); p<0.05)
3.2 (0.2)
(-1.9 (0.4); p<0.05) <0.05
Digit span backward (WAIS) 3.6 (0.3)(-0.8 (2.2); ns)
1.9 (0.1)
(-0.5 (0.7); p<0.05) <0.01
FAB total score 4.7 (1.5)(-4.5 (0.6); p<0.01)
7.5 (0.2)
(-3.3 (1.0); p<0.05) <0.01
Table 2. Cognitive synoptical results obtained by the two groups studied, at 12 months. Values are mean (SD); ns = not
significant. § Number of mistakes. In brackets, in each column, comparison within group, 24 months vs baseline,
reported as mean, SD, and p.
Tests Baseline sVAD Baseline AD
Barthel Index 87.41 ± 11.3 92.14 ± 0.11
Instrumental Activity of Daily Living 6.8 ± 0.34 5.84 ± 1.3
Table 3. TESTs results in the patients observed during follow-up.
Tests at 24 months sVAD AD Between groups (sVAD vsAD)
Barthel Index -25.17± 3.4 p<0.01 -13.57 ± 3.4 p<0.05 p<0.01
Instrumental Activity of Daily Living -1.7 ± 0.3 p<0.05 -3.4 ± 3.4p<0.01 p<0.01
Table 4. Results at 24 months: a comparison over baseline.
In summary, there are some important cognitive differences in the two groups: AD patients
did worse in MMSE, in arithmetic calculation and in digit tasks of WAIS, IADL; sVAD patients
did generally worse in FAB tests, Barthel Index.
From the behavioral perspective (Table 5-6), at baseline, the AD group had a worse score of
NPI and BEHAVE-AD, and their caregivers did have a heavier stress (RSS). On the contrary,
sVAD patients, at baseline did feel much more depressed (as stated by NPI partial scores, not
purposely evaluated in this topic) and did have a better insight in their situation. After 24
months, AD patients showed higher NPI and Behave scores; sVAD patients did show more
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insight. Surprisingly, the stress levels of the caregivers were not significantly different in the
two groups. sVAD patients did manifest more overt apathy, which increase during follow-up
and remained a major key point in behavior disturbances of these patients.
Moreover, there was a dramatic decrease, either in gait and equilibrium control, either in the
combined synoptical measure (of total score) in both groups, with sVAD patients showing a
constantly worse performance, compared to AD patients (Table 7-8).
baseline sVAD AD P value
RSS 24.7 (8.7) 36.1 (8.5) (p<0.01)
NPI 16.9 (0.3) 24.4 (5.2) (p<0.01)
CIR 3 (0.2) 2 (0.5) (p<0.05)
Table 5. Behavioral synoptical results. Values are mean (SD); ns = not significant.
24-month follow-up sVAD AD P value
RSS 47.5 (1.3)(+22.8 (5.9), <0.01)
45.2 (2.1)
(+9.1 (6.8), <0.05) ns
NPI 34.1 (0.8)(+17.2 (0.5), <0.01)
56.3 (4.5)
(+31.9 (1.1), <0.01) (p<0.01)
CIR 2.2 (0.3)(-0.8 (0.1), ns)
1.0 (0.3)
(-1.0 (0.3), <0.05) (p<0.01)
Table 6. Behavioral synoptical results. Values are mean (SD); ns = not significant; in brackets, in each column,
comparison within group, 24 months vs baseline, reported as mean, SD, and p.
Tests sVAD AD P value
TINETTI equilibrium 10.1 ± 0.1 14.3 ± 1.1 <0.001
TINETTI gait 10.2 ± 1.1 11.4 ± 0.3 <0.05
TINETTI tot. score 20.3 ± 1.2 25.7 ± 1.4 <0.001
Table 7. Gait TESTs results in the patients observed at baseline.





TINETTI equilibrium -5 ± 0.6 p<0.01 -3.4 ± 0.6 p<0.01 P<0.001
TINETTI gait -7.9 ± 1.1 p<0.01 -3.1± 1.1 p<0.01 P<0.001
TINETTI tot. score -12.9 ± 0.2 p<0.01 -6.5 ± 0.2 p<0.01 P<0.001
Table 8. Results at 24 months: a comparison over baseline at 24 months.
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Spearman’s rank correlation analyses indicated that there was a significant correlation between
Gait scores (total and separately, gait and equilibrium) and FAB scores (total Tinetti score/
FAB: r=0.81, p < 0.05 baseline; r=0.83, p < 0.01 over 24 months); gait Tinetti score/FAB: r=0.82,
p < 0.01 over baseline; r=0.87, p < 0.01 over 24 months); equilibrium Tinetti score/FAB: r=0.81,
p < 0.05 over baseline; r=0.83, p < 0.01 over 24 months) in sVAD.
Spearman’s rank correlation analyses indicated that there was a significant correlation between
Tinetti total, and equilibrium and gait score and BI over baseline, and 24 months (total Tinetti
score/BI: r=0.81, p < 0.05 over baseline; r=0.89, p < 0.01 over 24 months); gait Tinetti score/BI:
r=0.82, p < 0.01 over baseline; r=0.89, p < 0.01 over 24 months; equilibrium Tinetti score/BI:
r=0.84, p < 0.01 over baseline; r=0.89, p < 0.01 over 24 months) in sVAD.
Furthermore, we have found a correlation between Tinetti equilibrium score and NPI over 24,
months (equilibrium Tinetti/NPI: r=0.78, p<0.05 in sVAD; r=0.87, p<0.01 in AD), and Tinetti
gait score and NPI over 24 months (gait Tinetti /NPI: r= 0.78, p<0.05 in sVAD; r=0.86, p<0.01
in AD), and Tinetti total score and NPI over 24 months (Tinetti total score/NPI: r= 0.78, p<0.05,
in sVAD; r= 0.93, p<0.01 in AD).
Spearman’s rank correlation analyses indicated that there was a significant correlation between
Gait scores (total scores and separately, gait and equilibrium) and MMSE (total Tinetti score/
MMSE: r=0.81, p < 0.05 over 24 months in AD).
Surprisingly, we have found only a correlation between benzodiazepines intake and Tinetti
equilibrium score at 24 months (respectively r=0.77, p<0.05 in sVAD; r=0.84, p<0.01 in AD).
We distinguished typical from atypical neuroleptic intake (Table 9). Moreover, since quetia‐
pine, as an atypical neuroleptic, has a lower dopamine affinity compared to olanzapine, we
considered separately the compounds, concluding as follows:
• Typical neuroleptics: a significant correlation between haloperidol intake and Tinetti
equilibrium score at baseline and at 24 months (respectively: r=0.61, p<0.05, at baseline and
r=0.81, p<0.01 in AD patients; r=0.72, p<0.05 at 24 months in sVAD); between haloperidol
intake and Tinetti total score at baseline and 24 months (respectively: r=0.81, p<0.01 and
r=0.86, p<0.01 in AD; only at 24 months r=0.71, p<0.01 in sVAD); not significant correlation
between promazine chloridate intake and Tinetti sub-scores at baseline and at 24 months in
AD; we have found a positive correlation between the equilibrium score of Tinetti test and
promazine intake at 24 months in sVAD, not in AD group (r=0.74, p<0.05).
• Atypical neuroleptics: we have found a significant correlation between olanzapine intake
and Tinetti equilibrium score at 24 months in AD groups (none of sVAD took olanzapine
in our study) (r=0.74, p<0.05) and between olanzapine intake and Tinetti total score at 24
months (r=0.71, p<0.05); we have found a positive correlation between the equilibrium score
of Tinetti test and quetiapine intake at 24 months (respectively: r=0.79, p<0.05 in AD group;
r=0.82, p<0.01 in sVAD). The mean dose of olanzapine remained stable during the 24-month
follow-up (5.2-5.4 mg/day); on the contrary, quetiapine dosage increased up to 24-month
follow-up (56.3-89.6 mg/day).
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Drug utilization Baseline sVAD 24 months sVAD Baseline AD 24 months sVAD
Benzodiazepines
lorazepam, mean (±SD) dose
delorazepam, mean (±SD) dose
bromazepam, mean (±SD) dose
144 patients
1.27± 0.3 mg/day
1.21 ± 0.8 mg/day
2.11 ± 1.1 mg/day
289 patients
2.56 ± 0.65 mg/day
2.61 ± 1.29 mg/day
3.41 ± 0.8 mg/day
298 patients
3.94 ± 1.5 mg/day
3.1 ± 1.54 mg/day
4.6 ± 1.4 mg/day
304 patients
4.56 ± 1.65 mg/day
4.1 ± 1.89 mg/day
5.41 ± 1.8 mg/day
Typical neuroleptics




1.56 ± 0.54 mg/day
53.12 ± 12.23 mg/day
356 patients
2.34 ± 0.67 mg/day
59.12 ± 16.91 mg/day
88 patients
2.87 ± 1.54 mg/day
63.12 ± 7.2 mg/day
127 patients
3.56 ± 0.54 mg/day
67.12 ± 1.56 mg/day
Atypical neuroleptics
olanzapine, mean (±SD) dose
quetiapine, mean (±SD) dose
4 patients
0.0 ± 0 mg/day
37.5 ± 5.21 mg/day
23 patients
0 ± 0 mg/day
56.9 ± 3.5 mg/day
63 patients
5.6 ± 1.6 mg/day
66.8 ± 3.5 mg/day
83 patients
5.9 ± 2.94 mg/day
89.9 ± 3.5 mg/day
Table 9. A synopsis of the CNS drugs employed by the patients.
5. Discussion
Walking is a complex mechanism, based on motor control, step rhythm, muscular activation
and dys-activation, motor adjustment, attention, perception and so on. Spinal and brainstem
activation, which seems to be fundamental for quadrupeds, is not so dominant in humans,
where gait depends more on cortical and subcortical inputs [39].
The motor cortex, represented by distinct areas in the frontal lobes, receives a variety of inputs:
sensory areas, motor control structures, and modulatory pathways including the thalamus and
basal ganglia (BG). Movement planning and performance are strictly dependent from this
cluster of architectonically distinct frontal fields [40]. In particular, SMA activates immediately
before gait ignition in normal walking, suggesting a preparatory activity for each sub-
component of a movement sequence [41]. It has been suggested that this activity may reflect
sub-movement program selection, subsequently sent to the M1. On the other hand, BG
generate a phasic activity, which switches off SMA output and which is probably involved in
providing a non-specific cue both to trigger the sub-movement and to instruct the SMA to
prepare for the next, finally generating an “automatic” movement sequence [42, 7]. In conclu‐
sion, internal cues give rise to automatic movement sequences, as a result of the cooperation
of BG and SMA [7].
Gait control and in particular gait variability are deeply influenced by BG compensatory
activity [43]. Rosano and colleagues reported that subclinical brain vascular abnormalities
(WM infarcts and hyperintensities in MRI) were more frequent and severe in patients with a
greater variability of step length, independently from age, gender, and cognitive function [43].
Moreover, older people and patients with leukoaraiosis show higher-level gait alterations,
supporting the previous observations [39]. These data have been clinically confirmed by other
works by the LADIS group [11], by Srikanth et al. [44] and by Masdeu and Wolfson [45].
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Though, there are quite real differences among the few other studies on this point. It has been
established by Della Sala et al. [12] that even AD, in a sizeable proportion (40% of their
population) scored as having gait alteration. Though, it must be pointed out that the presence
of associated vascular pathology, declared by the writers themselves is a not indifferent
proportion (22.5%), even if they asserted that this could not account for the outcome. The
Authors declared that their patients showed the gait apraxia phenomenon, referring to deficits
of a relatively unitary function, with the reference to a theoretical model. Within the dichotomy,
proposed by Benke [46], between a conceptual system of motor acts and a system which
controls sensorimotor and spatial-temporal features of movement, gait apraxia would arise
from the impairment of the latter system. Gait apraxia suggested Della Sala et al. [12] should
also be distinguished from ideomotor apraxia, which hampers individual movements and
meaningless gestures. What we observed in our study was the dramatically significant
overcome of gait disturbances, either considering balance, either gait by itself, in pure sVAD
rather than in pure AD pathology. Gait imbalance in AD relates with progressive and dramatic
worsening of global cognitive functions (MMSE), with behavioural deterioration (NPI) and
with consequent drugs intake.
On the contrary gait and balance in sVAD is a very precocious symptom, which relates, from
the very beginning with frontal executive functions (FAB) and Barthel Index (BI) (Table 10).






Frontal executive functions (FAB) Global cognitive functions (MMSE)
Barthel Index (BI) Behavioral performance (NPI)
Drugs intake
Table 10. Summary: characteristics of gait disturbances in sVAD and AD patients.
Insofar, we hypothesize that even though gait apraxia is one of the symptoms declared in AD,
affecting highly routinized synergistic actions, it relates to AD cognitive worsening. On the
contrary, it is a key, precocious and very peculiar aspect of sVAD. Therefore, considering this
point, it can be found a good explanation of the phenomenon, in Liston et al. [7] work; they
suggested that microvascular alteration affecting the SMA, its connections in the periventric‐
ular WM, or the BG can cause a higher-level gait disorders (HLGDs), a hypothesis that seems
to agree with the concept of gait apraxia caused by any mesial frontal lesion (SMA anatomical
location) purposed by Meyer [47]. A further clinical confirmation is provided by current
evidence of gait abnormities in early vascular dementia, in particular when WM alterations
affect strategic pathways (linking the BG to the ventro-lateral nucleus of the thalamus and to
the SMA and frontal areas) [48, 49]; these critical locations compromise the timing cues from
the BG; the analogy to PD disconnections may suggest similar gait abnormalities. It is well
known and widely accepted that leukoaraiosis is associated with gait impairment, falls, and
worse equilibrium scores [1, 3-6, 8, 50]. Some authors suggest a spectrum of severity in gait
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disorders associated with WM abnormalities: on one side, severe gait disorder observed in
Binswanger’s disease with massive leukoaraiosis [7], on the other subclinical forms of gait
disorders can occur in patients with mild periventricular changes.
However, it has been demonstrated that many patients with vascular-HLGDs present with
disequilibrium as primary complaint rather than timing and movement ignition problems [4,
51, 7]. To explain this phenomenon it has been purposed that an alteration of the sensory/PMA
pathways, compromising the contribute to sub-movements initiation and control of sensory
input (proprioceptive, auditory, vestibular and visual information), may represent their
primary disorder [7]. The preservation of BG/SMA pathways guarantees the generation of
automatic, internally cued movements,
A clear point should be made in our study to the extremely strict exclusion criteria in AD and
in sVAD recruitment, basically founded on clinical signs and neuroimaging world-wide
accepted criteria. For example, in order to eliminate any confounding, we excluded patients
with brainstem lesions, which ischemic lesions could cause specific gait and equilibrium
abnormalities. Similarly, we considered also concurrent medications and co-morbidities, in
order to ensure that the gait and balance alterations observed should be considered as an
exclusive result of subcortical WM widespread damage. During the follow-up, a general
worsening, decrease of behavioural control, and consequent pharmacologic intake (neurolep‐
tics and benzodiazepines) stressed but did not cause directly the described gait abnormalities.
In conclusion, it might be stated that subcortical lesions cause “per se” the interruption of long
loop reflexes of deep white motor tracts and descending motor fibers arising from medial
cortical areas (see data and literature in: Guerini et al. [10], Moretti et al. [52]), translating in
gait alteration and imbalance. Moreover, subcortical vascular lesions involve fibres connecting
frontal cortex and subcortical structures, which are responsible for motivation, executive
function, planning and attention too (see in particular frontal eye fields). It has been suggested
(see data and Literature in Moretti et al. [52]) that the basal ganglia maintains cortically selected
motor set in the supplementary motor area and provides internal cues to the supplementary
motor area in order to enable each sub movement to be correctly linked together [53-56].
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